Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TG THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Tracking UnitSEC Table II · derivative / convertible security | Direct | 8,325 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 8,325 · Balance 8,325 F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant.
F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantStock Tracking Unit · Derivative | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020675 · rdgdoc.xml · derivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires not disclosed F1 · derivative.exercise_price: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2 · derivative.exercise_date: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 22:31 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 5,000 | $32.57 | $162,850.00 |
DisclosureSEC source: 0001437749-25-036358 · rdgdoc.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,816 F1 · shares: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Echelard's income tax obligations. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 21:47 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 10,000 | $36.94 | $369,400.00 |
DisclosureSEC source: 0001437749-25-020546 · rdgdoc.xml · nonDerivative · entry 2 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,816 F3 · shares: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Echelard's income tax obligations. F4 · price: Includes a weighted average price for shares sold in multiple transactions at prices ranging from $36.93 through $36.96, inclusive. Mr. Echelard undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:47 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 14,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020546 · rdgdoc.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,816 F1 · shares: Reflects a grant of restricted shares that will vest on June 12, 2026. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:35 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCommon Stock | 20,000 | $24.48 | $489,600.00 |
DisclosureSEC source: 0001437749-24-033950 · rdgdoc.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,098 F1 · shares: These shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Echelard's income tax obligations. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 19, 2024 Filed Jun 20, 2024 22:05 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 22,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020848 · rdgdoc.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,098 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2025. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-105389 · tm2327273-2_4seq1.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,848 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | PurchaseCommon Stock | 9,000 | $10.64 | $95,760.00 |
DisclosureSEC source: 0001104659-23-001901 · tm232483-2_4seq1.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,848 F1 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:31 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 43,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082018 · tm2221660-2_4seq1.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,848 F1 · shares: Reflects a grant of restricted shares that will vest on June 15, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084257 · tm2120405-2_4seq1.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,116 F1 · shares: Reflects a grant of restricted shares that will vest on June 18, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | SaleCOMMON STOCK | 30,000 | $40.05 | $1,201,500.00 |
DisclosureSEC source: 0001104659-20-134811 · tm2038329d1_4.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,116 F1 · price: Represents the weighted average sales price. The range of prices for such transaction was $39.90 to $40.13. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 23:49 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-076544 · tm2022959-3_4.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,116 F1 · shares: Reflects a grant of restricted shares that will vest on June 22, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:09 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 27,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-010888 · section16.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,116 F1 · shares: Reflects a grant of restricted shares that will vest on June 13, 2022. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007116 · section16.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,068 F1 · shares: Reflects a grant of restricted shares that will vest on June 26, 2021. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:07 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005704 · section16.xml · nonDerivative · entry 1 Echelard Yann · CIK 0001561958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,068 F1 · kind: Reflects a grant of restricted shares that will vest on June 16, 2020. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.